MedTrace Logo

Blood Proteome Profiling Identifies Biomarkers in Ischemic Stroke

NCT06729385 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-02-21

No results posted yet for this study

Summary

Endovascular thrombectomy and intravenous thrombolysis have become key therapeutic approaches for acute ischemic stroke. However, due to time window limitations, many patients are unable to receive reperfusion therapy, and the majority only receive supportive treatment. Ischemic stroke-related complications, including edema and infection, gradually subside after 7 days post-stroke, with the patient's condition generally stabilizing. Endogenous repair mechanisms will play a critical role in the coming months. This study aims to predict prognostic biomarkers for ischemic stroke patients who have not undergone reperfusion therapy, using blood proteomics data. All samples in our study are derived from this experiment. Our goal is to elucidate the molecular mechanisms underlying post-reperfusion prognosis and to provide insights for optimizing stroke treatment strategies.

Conditions

Interventions

DIAGNOSTIC_TEST

The blood Proteome Profiling

Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-02-20
Completion
2025-02-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06729385 on ClinicalTrials.gov